We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

75 hedge funds and large institutions have $264M invested in BioCryst Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $6.94M | Put options by funds: $3.7M

61% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 18

21% more capital invested

Capital invested by funds: $217M → $264M (+$46.2M)

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 73 → 75 (+2)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
75
Holders Change
+2
Holders Change %
+2.74%
% of All Funds
2.18%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
15
Increased
29
Reduced
18
Closed
13
Calls
$6.94M
Puts
$3.7M
Net Calls
+$3.24M
Net Calls Change
+$1.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.3M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.7M
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$10.2M
4
BFA
BlackRock Fund Advisors
California
+$4.35M
5
Morgan Stanley
Morgan Stanley
New York
+$2.9M

Top Sellers

Rank Fund Capital Flow
1
RCM
RA Capital Management
Massachusetts
-$9.48M
2
DM
Deerfield Management
New York
-$4.84M
3
TC
TFS Capital
Pennsylvania
-$4.53M
4
BIM
Bogle Investment Management
Massachusetts
-$2.81M
5
VM
VHCP Management
New York
-$2.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
USAA
26
United Services Automobile Association
Texas
$973K +$811K +128,076 New
Northern Trust
27
Northern Trust
Illinois
$874K +$72.7K +11,480 +11%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$862K -$46.5K -7,345 -6%
Goldman Sachs
29
Goldman Sachs
New York
$751K -$545K -86,139 -47%
DC
30
Deere & Company
Illinois
$732K +$39.4K +6,219 +7%
Bank of America
31
Bank of America
North Carolina
$726K +$70.7K +11,171 +13%
AQR Capital Management
32
AQR Capital Management
Connecticut
$724K +$603K +95,262 New
PP
33
PDT Partners
New York
$692K +$361K +57,043 +167%
U
34
UBS
Switzerland
$639K -$243K -38,352 -31%
Group One Trading
35
Group One Trading
Illinois
$541K +$230K +36,320 +104%
Westfield Capital Management
36
Westfield Capital Management
Massachusetts
$525K +$191K +30,100 +77%
State Street
37
State Street
Massachusetts
$446K +$61.4K +9,700 +20%
AL
38
Airain Ltd
Guernsey
$430K +$173K +27,308 +93%
Swiss National Bank
39
Swiss National Bank
Switzerland
$333K +$277K +43,800 New
Citadel Advisors
40
Citadel Advisors
Florida
$325K +$271K +42,803 New
WA
41
Waverly Advisors
Alabama
$286K +$63.3K +10,000 +36%
T
42
TradeWorx
New Jersey
$284K +$236K +37,343 New
Two Sigma Investments
43
Two Sigma Investments
New York
$281K -$555K -87,613 -70%
KIA
44
KCM Investment Advisors
California
$276K – – –
BCM
45
Bridgeway Capital Management
Texas
$241K – – –
CBOA
46
Commonwealth Bank of Australia
Australia
$225K +$99.1K +15,650 +112%
Wells Fargo
47
Wells Fargo
California
$198K -$49.7K -7,846 -23%
ProShare Advisors
48
ProShare Advisors
Maryland
$197K +$164K +25,886 New
Charles Schwab
49
Charles Schwab
California
$182K – – –
Barclays
50
Barclays
United Kingdom
$168K -$13.2K -2,082 -8%
1
2
3 4

BCRX Hedge Fund Activity: Q4 2013 in Review

75 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2013, worth a combined $264M — up 21% from $217M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new BCRX positions and 13 closed out — a net gain of 2 holders — while 29 added to existing stakes and 18 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $16.3M. The largest seller was RA Capital Management, cutting an estimated $9.48M.

  • 75 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2013, up from 73 in Q3 2013.
  • Funds reported $264M of BioCryst Pharmaceuticals stock for Q4 2013, up 21% quarter-over-quarter.
  • 15 funds opened new BioCryst Pharmaceuticals positions in Q4 2013 and 13 closed out, a net change of +2 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2013 was Fidelity Investments, an estimated $16.3M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2013 was RA Capital Management, an estimated $9.48M sold.

Based on aggregated 13F filings for Q4 2013.